|
|
Volumn 76, Issue 7, 2001, Pages 673-676
|
|
Regulatory issues for phage-based clinical products
|
|
Author keywords
Bacteriophage; Phage based clinical products; Regulatory issues
|
|
Indexed keywords
BACTERIOPHAGES;
DRUG DOSAGE;
REGULATORY COMPLIANCE;
TOXICITY;
THERAPEUTIC PRODUCTS;
BIOTECHNOLOGY;
BIOLOGICAL PRODUCT;
PLACEBO;
ANALYTIC METHOD;
BACTERIOPHAGE;
BIOTECHNOLOGY;
BRAIN SPONGIOSIS;
CELL CULTURE;
CONFERENCE PAPER;
COST;
CULTURE MEDIUM;
DECISION MAKING;
DRUG ISOLATION;
DRUG LABELING;
DRUG LEGISLATION;
DRUG MANUFACTURE;
DRUG PURIFICATION;
DRUG SAFETY;
DRUG STABILITY;
DRUG STERILITY;
GOOD MANUFACTURING PRACTICE;
HUMAN;
NONHUMAN;
PATIENT CARE;
PROCESS CONTROL;
QUALITY CONTROL;
VIRUS TRANSMISSION;
|
|
EID: 0034932845
PISSN: 02682575
EISSN: None
Source Type: Journal
DOI: 10.1002/jctb.435 Document Type: Conference Paper |
|
Times cited : (7)
|
|
References (6)
|
